Guardant Health, Inc. CEO Helmy Eltoukhy described the recent US Food and Drug Administration approval of the company’s liquid biopsy test Guardant360 CDx as a “watershed moment for comprehensive liquid biopsy” because it provides oncologists with the information they need to close the gap between clinical guidelines and clinical practice.
Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption
CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.
More from In Vitro Diagnostics
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.
More from Diagnostics
• By
Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.